$XBI $89.71 | +0.1%
Covid Updates
$
Pipeline Updates
$NBIX -0.1% Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan source
$CGEM -2.4% Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients source
$KRYS +2.4% Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine. source
$NBIX -0.1% Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022. source
$PRTA 0.0% Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease. source
$RAPT -0.6% RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis. source
$INAB -2.7% IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant. source
$BIIB +0.3% Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis. source
$ALZN -0.8% Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s. source
$ENDP +3.0% Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials. source
$BBIO +0.7% BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo. source
$PRVB -2.8% Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101. source
$CARA 0.0% Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus. source
$VSTM +10.9% Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors. source
$ASLN +6.6% ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting. source
$AMRN -0.3% Amarin Receives Reimbursement for VAZKEPA® in Sweden. source
$AVIR +1.2% Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting. source
$GLPG +0.7% Jyseleca® approved in Japan for ulcerative colitis. source
$INCY +0.6% Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies. source
$KRYS +2.4% New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting. source
$INCY +0.6% Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo. source
Business Updates
$JAZZ -1.6% Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics. source
$AXSM -0.7% Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience. source
$EGRX +8.3% Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc. source
Posted by FS/JM
Commentaires